Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG-fluorescence imaging for intraoperative breast cancer margins evaluation: a dose-timing study
2023-504024-26-00Phase 2Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in Infiltrating Ductal Carcinoma (IDC), sponsored by Institut Jules Bordet. Primary endpoint: Accuracy of ICG-fluorescence imaging technique for the detection of positive (involved) surgical margins. Planned start Dec 2023; status: authorised.
02
Drugs
indocyanine green
03
Conditions
Infiltrating Ductal Carcinoma (IDC)
Beyond the preview
Go deeper on 2023-504024-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504024-26-00.